Loading organizations...

Chinook Therapeutics is a technology company.
Chinook Therapeutics develops precision medicines for chronic kidney diseases. It leverages a proprietary discovery platform that integrates single-cell RNA sequencing, human-derived organoids, and artificial intelligence to identify novel targets and therapies, moving beyond symptomatic treatments to address underlying disease mechanisms.
The company was founded in 2016 by Srinivas Akkaraju, M.D., Ph.D. The initial insight was to take a long-term strategic approach to value creation in the biopharmaceutical space, specifically focusing on the significant unmet medical needs within kidney disease by applying advanced genomic and computational methods.
Chinook Therapeutics targets patients suffering from severe and rare chronic kidney disorders. The company's vision is to deliver targeted therapies that significantly improve outcomes for these patients, ultimately striving to transform the treatment landscape for kidney diseases with precision medicine.
Chinook Therapeutics has raised $171.0M across 2 funding rounds.
Chinook Therapeutics has raised $171.0M in total across 2 funding rounds.
Chinook Therapeutics is a clinical‑stage biopharmaceutical company focused exclusively on developing precision medicines to treat kidney diseases, with a stated mission to “change the course of kidney care” and make dialysis and transplant unnecessary for patients with progressive kidney disorders.[1][4]
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech/Biopharma Landscape
Quick Take & Future Outlook
If you’d like, I can: (a) produce a concise one‑page investor brief with timeline and key catalysts, (b) extract and summarize the latest clinical data readouts for each lead program, or (c) map competitive companies working in IgA nephropathy and related renal areas.
Chinook Therapeutics has raised $171.0M in total across 2 funding rounds.
Chinook Therapeutics's investors include Ally Bridge Group, Apple Tree Partners, Avidity Partners, EcoR1 Capital, Janus Henderson Investors, Monashee Investment Management, Northleaf Capital Partners, OrbiMed, Rock Springs Capital, Samsara BioCapital, Sphera Biotech Master Fund, Surveyor Capital.
Chinook Therapeutics has raised $171.0M across 2 funding rounds. Most recently, it raised $106.0M Other Equity in August 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 18, 2020 | $106.0M Other Equity | Ally Bridge Group, Apple Tree Partners, Avidity Partners, EcoR1 Capital, Janus Henderson Investors, Monashee Investment Management, Northleaf Capital Partners, OrbiMed, Rock Springs Capital, Samsara BioCapital, Sphera Biotech Master Fund, Surveyor Capital, Versant Ventures | |
| Aug 1, 2019 | $65.0M Series A | Versant Ventures | Sam Hall, Srinivas Akkaraju |